In this Pharmaceutical Executive video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to accessing and participating in clinical research.
So indeed, women with chronic illnesses, face specific challenges when it comes to accessing appropriate treatment. And actually, it starts with having relevant information and data from clinical trials. So first of all, to be clear, women's health includes reproductive health, but also covers general conditions that may affect women differently, or disproportionately, like higher prevalence, higher disease burden for women. And I'm just going to give you a couple of examples.
In rheumatic diseases for example, research show that women can experience longer delays in diagnosis, greater pain, anxiety, stress, and can as a result be less active. The same way in psoriatic diseases, which is a disease that affects both skin and joints, women experience a greater feeling of stigmatization are more likely to suffer from stress loneliness than men. And maybe another example we can think about is one of three women will suffer from fragility fracture due to osteoporosis during her lifetime. And despite all that, health challenges for women are still consistently overlooked with studies that ignore the contribution of gender differences in significant condition. So as a result, treatment guidelines, at least at the moment do not recognize gender as a reason to consider different approaches to their care. And policies and frameworks need to ensure they reflect an equality-based approach to the care of women.
Actually, health systems that take account, gender differences in their public health strategies are more likely to be successful and have a greater societal impact. We know that now. Right? So, most women with chronic illnesses are often diagnosed during the height of their careers and their reproductive years. And then they will face specific challenges. One of them could be the desire to continue working, but sometimes building a family as well when managing their disease. And it is critical to improve the standard of care for these women. So, they don't have to make tradeoffs between controlling their disease or planning their family and daily living the life they choose.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.